TrialPanorama/Dataset huggingface dataset:
Please assess the completion status of the following clinical trial:

Trial Title: Post Market Evaluation of Aer-O-Scope Visualization

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: SCREENING
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. Subject is indicated for screening, diagnostic (minor complaints such as rectal bleeding or minor abdominal pain) or surveillance colonoscopy~2. Subject willing to undergo tandem colonoscopies with Aer-O-Scope Colonoscope and a conventional colonoscope (including a single colon preparation bowel cleansing)~3. Subject between the ages of 45 and 75 (patients between the ages of 45 and 50 must have a family history of a first degree relative with onset of colon cancer before the age of 60).~4. Subject is able to understand and willing to sign informed consent form~Exclusion Criteria:~1. Personal history of colorectal neoplasia including familial adenomatous polyposis or hereditary nonpolyposis, colon cancer (HNPCC).~2. Diagnosis of active (flaring) inflammatory bowel disease (active ulcerative colitis or Crohn's colitis), bowel obstruction, or acute diverticulitis, or known severe diverticulosis, fecal incontinence or any known large-bowel disease that would require a predetermined therapeutic colonoscopy (non-screening, non-diagnostic or non-surveillance cases)~3. Severe gastrointestinal tract-related symptoms, or complaints, suggesting performance of a pre-determined therapeutic colonoscopy (non-screening, non-diagnostic or non-surveillance cases)~4. History of colonic resection~5. Clinically significant cardiovascular or pulmonary disease.~6. Cancer or other life threatening disease or significant chronic condition that puts the subject at risk.~7. Blood-clotting disorders and/or current anticoagulant therapy (Subjects taking up to 100mg aspirin for prophylactic treatment are acceptable for this study)~8. Pregnancy~9. Previous radiation therapy to the abdomen~10. Morbid Obesity (BMI \> 40 kg/m2)~11. Drug abuse or alcoholism~12. Subject is bed-ridden and/or unable to adequately communicate~13. Subject is under custodial care~14. Subject has a history of psychiatric disorders which would prevent compliance with study instructions~15. Participation in a clinical study within the previous 30 days

- Gender: ALL
- Minimum Age: 45 Years
- Maximum Age: 75 Years
- Healthy Volunteers: t

Study Arms:
- Aer-O-Scope First (Type: ACTIVE_COMPARATOR): Patients in this arm will undergo colonoscopy using the Aer-O-Scope followed by colonoscopy using a conventional colonoscope
- Conventional Colonoscope First (Type: ACTIVE_COMPARATOR): Patients in this arm will undergo colonoscopy using a conventional colonoscope followed by colonoscopy using the Aer-O-Scope

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: feasibility
Please assess the completion status of the following clinical trial:

Trial Title: Radial Optic Neurotomy in Central Retinal Vein Occlusion : a Randomized Trial

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Central Retinal Vein Occlusion oedematous or hemorrhagic (at fundus exam and at fluorescein angiography)~* Visual Acuity (VA) ≤ 20/200 with ETDRS charts~* Decreased VA since more than 1 month, less than 3 months~* Common care recommendations for CRVO during the period before recruitment (Control ocular pressure if associated hypertension or glaucoma ; Hemodilution if hematocrit ≥ 38% ,if no cardio-vascular contra-indication, to maintain hematocrit under 38% during 6 weeks ; Troxerutin (3 /d) and aspirin (100 - 160 mg/d) ; Clinical and angiographic controls to look for retinal ischemia indicating laser PRP to prevent neovascular glaucoma.~* Signed informed consent.~Exclusion Criteria:~* Ischemic CRVO : 1- More than 30 disc diameters of ischemia at fluorescein angiography and/or •2- If Angiogram is uninterpretable because of hemorrhages, deficit of afferent pupillary reflex 0.9 with photographic filters (proposed by Hayreh) with indication to do laser PRP or laser PRP already done,~* Rubeosis or neovascular glaucoma,~* Bilateral diabetic retinopathy preproliferative or proliferative,~* Uncharacterized coagulation disease, or anticoagulant treatment,~* Untreated systemic disease (diabetes, severe high blood pressure, Cardiac failure) ou eye disease (glaucoma),~* Contra-indication or documented allergy to troxerutin or platelet anti-aggregating agents,~* Contra-indication to surgical procedure~* incapacity to received an informed consent, incapacity to follow all the study schedule

- Gender: ALL
- Minimum Age: 50 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- 1 (Type: NO_INTERVENTION): Standard treatment of central retinal vein occlusion : the rheologic correction
- 2 (Type: EXPERIMENTAL): Standard treatment of central retinal vein occlusion : the rheologic correction and surgery associating pars plana vitrectomy and radial optic neurotomy

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: lack of efficacy
Please assess the completion status of the following clinical trial:

Trial Title: Study of Pimecrolimus Treatment for Atopic Dermatitis of African American Children

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: SINGLE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* African American children aged 2 to 17 years~* mild to moderate atopic dermatitis~Exclusion Criteria:~* m-EASI less than 3 at baseline~* allergy to Elidel or components~* use of oral steroids, immunosuppressive agents,cytostatics of phototherapy within 4 weeks prior to study.~* previous continuous or non-continuous use of pimecrolimus or tacrolimus for greater than 11 months within 2 weeks of enrollment.~* active skin infections.~* immunocompromised patients.~* previous history of skin cancer or lymphoma~* any hypopigmentation in study areas~* pregnant or breastfeeding~* participation in another investigational trial

- Gender: ALL
- Minimum Age: 2 Years
- Maximum Age: 17 Years
- Healthy Volunteers: f

Study Arms:
- Pimecrolimus (Type: EXPERIMENTAL): Pimecrolimus 1% cream
- 2 (Type: PLACEBO_COMPARATOR): Placebo cream over affected study area

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Influence of Alcohol Marketing Stimuli in Adults With Regular Alcohol Consumption

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: COHORT
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Patient over 18 years of age~* Patient with moderate to severe alcohol use disorders (beyond 3 out of 11 criteria on the DSM-5 scale)~* Non-opposition of the patient~Exclusion Criteria:~* Minor patient~* Patient who has already participated in phase 1 of the project~* Non-comprehension of the written French language~* Refusal to participate in the study~* Patient of legal age, deprived of liberty by a judicial or administrative decision or unable to express their consent

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Effect of IV Vitamin C, Thiamine, and Steroids on Mortality of Septic Shock

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Patients admitted to medical intensive care unit (MICU) for less than 24 hours, who are hypotensive despite a fluid bolus of 30 mL/kg and who are requiring pressors to keep MAP \> 65 of at least 5 mcg/min of levophed or equivalent and whose shock is clinically suspected to be secondary to sepsis.~* In addition, stress dose corticosteroids, hydrocortisone 50mg IV Q6hrs, will have to have been started or intended to be started.~Exclusion Criteria:~* Contraindication to corticosteroids, thiamine, or vitamin C~* Treating physician opposed to administering corticosteroids to the patient~* Age \< 18 years~* Pregnancy~* DNR/DNI/limitations of care~* Patients with a fatal underlying disease who are unlikely to survive to hospital discharge~* Patients with a primary admitting diagnosis of an acute cerebral vascular event, acute coronary syndrome, active gastrointestinal bleeding, burn or trauma~* Requirement for immediate surgery~* Patients with HIV and a CD4 \< 50 mm2~* Patients with known glucose-6 phosphate dehydrogenase (G-6PD) deficiency.8~* Involvement in another clinical trial

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Vitamin C and Thiamine (Type: EXPERIMENTAL): IV vitamin C, 1500mg in 50ml of normal saline every six hours, infused over one hour and IV Thiamine 200mg in 50ml of 5% dextrose every 12 hours, for 4 days or until discharge from the intensive care unit, whichever comes first.
- Placebo (Type: PLACEBO_COMPARATOR): 50ml of IV normal saline every six hours and 50ml of IV 5% dextrose every 12 hours, for 4 days or until discharge from the intensive care unit, whichever comes first.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: lack of efficacy
Please assess the completion status of the following clinical trial:

Trial Title: Increasing the Winter Community Participation of Older Adult Wheelchair Users

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: OTHER
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Age 70 or older, user of a manual or power wheelchair or scooter for outdoor mobility~* Self-identifies a reduction in community participation throughout the winter months~* Community-dwelling~* Lives within the perimeter of Winnipeg.~Exclusion Criteria:~* Geriatric Depression Scale-SF score of 6 or more~* Montreal Cognitive Assessment score of 25 or less

- Gender: ALL
- Minimum Age: 70 Years
- Maximum Age: None
- Healthy Volunteers: t

Study Arms:
- Behavioural (Type: OTHER): Participant-identified community based activity

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Phase I Study of Lenalidomide, Rituximab and Ibrutinib in Relapsed/Refractory Chronic Lymphocytic Leukemia (CLL)

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Previously treated chronic lymphocytic leukemia or small lymphocytic lymphoma that requires treatment~* No prior systemic treatment within 4 weeks of enrollment~* No corticosteroids within 2 weeks prior to study entry~* Measurable disease must be present~* No concomitant anti-cancer therapies~* ECOG status \</= 2~* Patients with HIV infection are eligible~* Patients with treated CLL or SLL in CNS are eligible~* Non-pregnant and non-nursing~* Life expectancy greater than 60 days~* Adequate bone marrow, kidney and liver function~* No major surgery within 28 days or minor surgery within 5 days of starting treatment~Exclusion Criteria:~* History od Richter's transformation~* History of prior allogeneic transplant~* Radioimmunotherapy within 1 year of enrollment~* Prior Bruton's tyrosine kinase inhibitor or lenalidomide~* History of allergic reactions to compounds similar to ibrutinib, lenalidomide or rituximab or hypersensitivity~* active or uncontrolled autoimmune hemolytic anemia or ITP~* Transfusion-dependent thrombocytopenia or bleeding disorders~* Active hepatitis B or C infections~* History of known Human Anti-Chimeric Antibody positivity~* History of erythema multiforme, toxic epidermal necrolysis, or Stevens-Johnson syndrome~* History of uncontrolled seizures~* Autoimmune disorder that requires active immunosuppression~* Stroke or intracranial hemorrhage within last 6 months~* History of congestive heart failure, myocardial infarction, unstable angina, uncontrolled arrhythmia or any Class 3 or 4 heart disease in the last 6 months~* No prior malignancy except if treated with curative intent with no active disease for more than 3 years; adequately treated non-melanoma skin cancer or cervical cancer in situ~* using warfarin or similar Vitamin K antagonists Unable to swallow capsules or disease significantly affecting gastrointestinal function or inhibiting small intestine absorption

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Lenalidomide, Ibrutinib, Rituximab (Type: EXPERIMENTAL): Rituximab on day 1, lenalidomide days 1-21 and ibrutinib continuously for 6 cycles or until disease progression or intolerance to the combination. Single agent ibrutinib will then be continued until disease progression or intolerance.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: EMA Baseline Screening System for Therapists Who Treat Youths With Depressive Symptoms

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: SCREENING
- Time Perspective: None
- Masking: DOUBLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria for Patients:~* Owning a mobile phone with permanent access to the internet,~* Scoring from eleven to nineteen points in the PHQ-9 questionnaire.~* Having completed the eighth grade of basic education.~Exclusion Criteria for Patients:~* Being diagnosed with Depression with psychotic symptoms,~* Having a depressive episode as part of a bipolar disorder diagnosis~* Having suicidal thoughts and/or behaviour as measured by the PHQ-9 and evaluated by the physician.~* Alcohol and/or substance abuse.~Inclusion Criteria for Therapists:~- Having 1 or more years of clinical experience.~Exclusion Criteria for Therapists:~* Having less than 1 year of clinical experience.~* Having participated in the design of PDF reports.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 24 Years
- Healthy Volunteers: f

Study Arms:
- Intervention group (Type: EXPERIMENTAL): Patients in experimental group will receive EMA prompts. Therapists in this group will receive a summarized PDF report before the beginning of the first psychotherapy session. The report will include graphic summarized data from the EMA prompts.
- Control group (Type: ACTIVE_COMPARATOR): Patients in control group will receive the EMA prompts in the same manner as patients in the experimental group.~Therapists in this group will not receive the PDF reports, and instead will get raw scores from a screening evaluation conducted with patients in the recruitment phase of the study.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Detection of PPROM With AmniSure PAMG-1 Rapid Immunoassay

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: COHORT
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* women presenting to assessment at the labour and delivery unit at RUH with suspected PPROM between 16+0 and 36+6 weeks gestation~* consent to enrollment~Exclusion Criteria:~* vaginal bleeding~* active labor (cervical dilation \> 2 cm or effacement \> 80%)~* multiple pregnancy~* fetal anomalies~* placenta previa~* fluid loss per vagina \> 7 days~* prior inclusion in the study

- Gender: FEMALE
- Minimum Age: None
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- PPROM (Type: None): All women presenting to assessment at the labour and delivery unit at RUH with suspected PPROM between 16+0 and 36+6 weeks gestation.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: COVidIVERmectin: Ivermectin for Treatment of Covid-19

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: SEQUENTIAL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE2
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Age \>=18 years~* Positivity at RT-PCR per SARS_CoV2 (nasopharyngeal swabs)~* Consent to participation to the study and to the processing of personal data~* COVID-19 Severity Score \< 3~* Patient able to take oral drugs~Exclusion Criteria:~* Pregnant or lactating women (pregnancy test not required, if doubt patient is excluded)~* Subjects suffering from known CNS diseases~* Lack of (or inability to provide) informed consent~* Patient under dialysis~* Any severe medical condition with a prognosis of \< 6 months~* Patients under warfarin treatment~* Patients under antiviral treatment~* Patients under chloroquine phosphate or hydroxychloroquine

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- I_600 (Type: EXPERIMENTAL): ivermectin 600 μg/kg daily for 5 consecutive days (I_600) + placebo
- I_1200 (Type: EXPERIMENTAL): ivermectin 1200 μg/kg daily at empty stomach with water for 5 consecutive days
- Placebo (Type: PLACEBO_COMPARATOR): placebo

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Evaluate the Efficacy of the Treatment of Iatrogenic Subcutaneous Abdominal Wounds (ISAW) After Surgery by Application of Negative Pressure Wound Therapy (NPWT) in Comparison to Standard Conventional Wound Therapy (SCWT) of the Clinical Routine

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Acute subcutaneous abdominal wound-healing impairment after surgical intervention~* Sizes of wound opening (maximum diameter ≥ 3 cm)~* Wound surface ≥ 9 qcm~Exclusion Criteria:~Lack of infrastructure for outpatient continuation of treatment and study-specific interventions~* Existence of an open abdominal fascia~* Acute serious organ failure~* Application of an other active vacuum device at the wound treated during the study conduct within 8 days before screening visit~* Ongoing / during 3 weeks after chemo therapy~* Ongoing / during 3 weeks after radiation therapy Contraindications in accordance with the safety precautions issued by the FDA or the companies

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Negative Pressure Wound Therapy (Type: EXPERIMENTAL): Used therapy systems
- Standard Conventional Wound Therapy (Type: ACTIVE_COMPARATOR): Standard conventional wound therapy according to current evidence-based guideline (basic and advanced methods of wound treatment)

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Probiotics for the Prevention of Antibiotic-Associated Diarrhea

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. Participants will be children aged 1 year to 17 years admitted to the General Pediatric inpatient unit at The Hospital for Sick Children (Site 1) or McMaster Children's Hospital (Site 2).~2. Participants will be prescribed IV antibiotics with a planned duration of 1 or more days, and a total course of both IV and oral antibiotics, if applicable, of no more than 28 days.~3. Parent (if parent-report) or patient (if patient-report) is able to communicate in English (read, write, speak).~Exclusion Criteria:~1. Parental or patient (e.g. child \> 12 years old) report of current diarrhea, diarrhea within the last week.~2. Lactose intolerance.~3. Allergies to strawberry, dried citrus pulp, or any other components of the study product.~4. Immuno-compromised patients or those on immunosuppressive agents (e.g. heart or kidney transplant, complex care, sickle cell disease, chemotherapy agents, oral prednisone).~5. Patients with known or potentially compromised gut integrity (e.g. short gut, Inflammatory Bowel Disease, Celiac disease, Irritable Bowel Syndrome, nasogastric, nasojejunal or gastrostomy tube).~6. Children with serious and/or unstable medical conditions (e.g. diabetes, cardiovascular, renal, lung, psychiatric illness, bleeding disorders, etc.).~7. Children admitted to a medical or surgical subspecialty unit.~8. Patients enrolled in another study.~9. Patients previously randomized to this study.~10. Patient is pregnant.

- Gender: ALL
- Minimum Age: 1 Year
- Maximum Age: 17 Years
- Healthy Volunteers: f

Study Arms:
- Probiotic (BioK+) (Type: EXPERIMENTAL): Children will receive 10-40 billion CFUs/day of Bio-K+ (Lactobacillus acidophilus CL1285, Lactobacillus casei LBC80R and Lactobacillus rhamnosus CLR2), with dose based on their weight. The product will be administered as a strawberry flavored tub of milk.
- Placebo (Type: PLACEBO_COMPARATOR): Strawberry flavored tub of milk, identical (taste, color, odor) to the active Bio-K+ treatment.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues